Variation in the cost of medications for the treatment of colorectal cancer

American Journal of Managed Care

Volumn 14, Issue 11, 2008, Pages 717-725

  Ferro, Salvatore A ^a   Myer, Brian S ^a   Wolff, Debra A ^b   Poniewierski, Marek S ^b   Culakova, Eva ^b   Cosler, Leon E ^a,b   Scarpace, Sarah L ^a   Khorana, Alok A ^b   Lyman, Gary H ^c  

^a Union University ^*  (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DOLASETRON MESILATE; ERYTHROPOIETIN; ERYTHROPOIETIN ALFA; FLUOROURACIL; FOLINATE CALCIUM; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GROWTH FACTOR; IRINOTECAN; MONOCLONAL ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ONDANSETRON; OXALIPLATIN; PALONOSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DRUG COST; DRUG DOSE REGIMEN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 56749144020     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-130.
2. Starling N, Tilden D, White J, Cunningham D. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer. 2007;96(2):206-212.
3. Thorpe KE. The rise in health care spending and what to do about it. Health Aff (Millwood). 2005;24(6):1436-1445.
4. Smith RE, Renaud RC, Hoffman E. Colorectal cancer market. Nat Rev Drug Discov. 2004;3(6):471-472.
5. Jansman FG, Postma MJ. Costs of chemotherapy in the treatment of colorectal cancer. Eur J Health Econ. 2006;7(2):137-144.
6. Costa NM. The morality price to prolong median survival beyond 21 months in metastatic colorectal cancer patients. Future Oncol. 2005;1(4):443-444.
7. Vanchieri C. When will the U.S. flinch at cancer drug prices? J Natl Cancer Inst. 2005;97(9):624-626.
8. Schrag D. The price tag on progress: chemotherapy for colorectal cancer. N Engl J Med. 2004;351(4):317-319.
9. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer, results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11(10):1879-1887.
10. Saltz LB, Cox JV, Blanke C, et al; Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343(13):905-914.
11. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-2947.
12. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345.
13. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23(16):3697-3705.
14. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
15. Hoffman JM, Shah ND, Vermeulen LC, et al. Projecting future drug expenditures: 2006. Am J Health Syst Pharm. 2006;63(2):123-138.
16. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007;25(2):180-186.
17. Viale PH, Fung A, Zitella L. Advanced colorectal cancer: current treatment and nursing management with economic considerations. Clin J Oncol Nurs. 2005;9(5):541-552.
18. Paramore LC, Thomas SK, Knopf KB, et al. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6(1):52-58.
19. van den Hout WB, van den Brink M, Stiggelbout AM, et al. Cost-effectiveness analysis of colorectal cancer treatments. Eur J Cancer. 2002;38(7):953-963.
20. Jansman FG, Postma MJ, van Hartskamp D, et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther. 2004;26(4):579-589.
21. Cunningham D, Falk S, Jackson D. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer. 2002;86(11):1677-1683.
22. Hale JR Cohen DR, Maughan TS, et al. Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer. Br J Cancer. 2002;86(11):1684-1690.
23. Jansman FG, Postma MJ, Brouwers JR. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics. 2007;25(7):537-562.
24. Hillner BE, Schrag D, Sargent DJ, et al. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer. 2005;104(9):1871-1884.
25. Krzyzanowska MK, Treacy J, Maloney B, Lavino A, Jacobson JO. Development of a patient registry to evaluate hospital admissions related to chemotherapy toxicity in a community cancer center. J Oncol Pract. 2005;1(1):15-19.
26. Smith RE. Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. J Natl Compr Canc Netw. 2006;4(7):649-658.
27. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004;22(21):4302-4311.
28. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524-4531.
29. Budman DR, Berry DA, Cirrincione CT, et al; Cancer and Leukemia Group B. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998;90(16):1205-1211.
30. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 [published correction appears in J Clin Oncol. 2003;21(11):2226]. J Clin Oncol. 2003;21(8):1431-1439.
31. Hryniuk W, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol. 1987;14(4 suppl 4):3-11.
32. Centers for Medicare & Medicaid Services Web site. July 2006 quarterly average sales price (ASP) Medicare Part B drug pricing file, effective July 1, 2006, and revisions to January 2006 and April 2006 quarterly ASP Medicare Part B drug pricing files. Baltimore, MD: Dept of Health and Human Services; 2006. http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5110.pdf. Accessed August 7, 2008.
33. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23-30.
34. Cassidy J, Tabemero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22(11):2084-2091.
35. Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol. 1997;15(8):2910-2919.
36. Chu E, DeVita V. Physicians' Cancer Chemotherapy Drug Manual 2003. Sudbury, MA: Jones & Bartlett; 2003.
37. Thomson Healthcare. DrugPoints System: Micromedex Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Healthcare; 2006.
38. Lyman GH. Risks and consequences of chemotherapy-induced neutropenia. Clin Cornerstone. 2006;8(suppl 5):S12-S18.
39. Lyman GH. Chemotherapy dose intensity and quality cancer care. Oncology (Williston Park). 2006;20(14 suppl 9):16-25.
40. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10(6):427-437.
41. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Antiemesis. Version 2. Jenkintown, PA: National Comprehensive Cancer Network; 2006.